Compare Incyte Corporation (INCY) vs SS&C Technologies Holdings Inc. Common Stock (SSNC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs SS&C Technologies Holdings Inc. Common Stock — how do they compare? Incyte Corporation trades at $114.95 (market cap $22.63B), while SS&C Technologies Holdings Inc. Common Stock trades at $83.32 (market cap $19.25B). The key difference: Incyte Corporation is the larger of the two by market cap, and SS&C Technologies Holdings Inc. Common Stock pays a 1.46% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and SS&C Technologies Holdings Inc. Common Stock for 0 Days on average.
| INCY | SSNC | |
|---|---|---|
Market Cap | $22.63B | $19.25B |
Volume | 1,869,988 | 1,341,767 |
Sector | Health | Technology |
52-Week High | $129.93 | $89.62 |
52-Week Low | $86.17 | $62.05 |
Typical Hold Time | 33 Days | 0 Days |
Enterprise Value | $18.13B | $26.59B |
Dividend Yield | — | 1.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $108.62, down 2.46% on the day, with a bearish technical signal despite strong fundamental performance. The company reported robust 2025 results with $5.14B revenue and $1.29B net income, showing significant margin expansion. Recent FDA approval for Atebrioz and pipeline developments support growth beyond JAKAFI exclusivity. Analyst consensus remains positive with a $133.14 price target, though technical indicators show selling pressure near-term.
The outlook balances strong fundamentals against technical weakness. Upside potential exists from pipeline execution and $4B sales target, but risks include JAKAFI patent expiration post-2029 and current bearish momentum. With 52% buy ratings and solid cash flow generation, the stock offers value at current levels for patient investors despite near-term volatility.
SSNC trades at $81.52, up 0.65% on the day, with a neutral technical signal. The company has consistently beaten earnings estimates in recent quarters (Q4 2025, Q1 2026, Q2 2026) and shows solid fundamentals, including a 13.16% net income margin and 12.73% ROE. Recent news highlights new client wins and AI-driven product enhancements, reinforcing its market position.
The outlook is positive, supported by strong analyst consensus (70.83% Buy rating) and a $91.50 price target, implying ~12% upside. Key risks include execution of growth initiatives and competitive pressures in the financial technology sector. The stock presents a compelling opportunity for investors seeking a fundamentally sound company with recurring revenue streams.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About SS&C Technologies Holdings Inc. Common Stock
SS&C Technologies Holdings, Inc. provides software and outsourced services for financial services and healthcare organizations, covering fund accounting, portfolio management, trading support, and regulatory reporting, and operates as a hedge fund and private equity administrator and mutual fund transfer agent.
Read more on SSNC →
